Skip to main content

View full-text article in PMC

. 2020 Aug 27;25(11):1977–1984. doi: 10.1007/s10147-020-01736-4

Table 4.

DVH parameters and feasibility according to HR-CTV

	All (n = 39^a)	HR-CTV < 40 cm³ (n = 22)	HR-CTV ≥ 40 cm³ (n = 17)
HR-CTV D90	73 (60–87) Gy	75 (67–87) Gy	69 (63–74) Gy
Bladder D2 cm³	74 (58–95) Gy	78 (60–95) Gy	70 (62–90) Gy
> 75 Gy^b	45% (18/40)	55% (12/22)	35% (6/17)
Rectum D2 cm³	57 (51–73) Gy	55 (51–63) Gy	57 (53–73) Gy
> 66 Gy^b	8% (3/40)	0% (0/22)	18% (3/17)
Sigmoid D2 cm³	62 (50–71) Gy	62 (50–69) Gy	62 (54–71) Gy
> 66 Gy^b	20% (8/40)	23% (5/22)	18% (3/17)
Small bowel D2 cm³	56 (45–72) Gy	57 (46–72) Gy	53 (45–67) Gy
> 66 Gy^b	13% (5/40)	18% (4/22)	6% (1/17)

DVH parameters: total EQD2 of EBRT and all ICBTs (HR-CTV; α/β = 10, OARs; α/β = 3). HR-CTV: volume at the 1st ICBT

^a1 patient without ICBT was excluded

^bTarget dose